VIVS · VivoSim Labs, INC.
Substantial doubt about the company's ability to continue as a going concern.
“Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Separately, our independent registered public accounting firm included in its opinion for the year ended March 31, 2026 an explanatory paragraph referring to our recurring losses from operations and expressing substantial doubt in our ability to continue as a going concern without additional capital becoming available.”View the 10-Q filed Aug 12, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-01-27 | Gobel David |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
15,000 |
| 2026-01-27 | Murphy Keith |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. |
Common Stock
|
15,000 |
| 2026-01-27 | Milhous Alison Tjosvold |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. |
Common Stock
|
15,000 |
| 2026-01-27 | Cohen Douglas Jay |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. |
Common Stock
|
15,000 |
| 2026-01-27 | STERN ADAM K |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. |
Common Stock
|
15,000 |
| 2025-11-25 | Sethi Amar Akhtar |
Chief Scientific Officer |
Award↑
Filing footnotes — Options (right to buy) (Direct)
The option vests over a four year period, with 25% of the total number of shares subject to the option vesting on November 24, 2026, and the balance vesting in 12 equal quarterly installments thereafter. |
Options (right to buy)
|
53,500 |
| 2025-11-24 | Sethi Amar Akhtar |
Chief Scientific Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-11-17 | Gobel David |
Director |
Sell↑
Filing footnotes — Common Stock (Direct)
Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split. |
Common Stock
|
3,266 |
| 2025-08-11 | Lialin Tony Serge |
Chief Commercial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-08-11 | Lialin Tony Serge |
Chief Commercial Officer |
Award↑
Filing footnotes — Options (right to buy) (Direct)
The option vests over a four year period, with 25% of the total number of shares subject to the option vesting on the August 11, 2026, and the balance vesting in 12 equal quarterly installments thereafter. |
Options (right to buy)
|
40,000 |
| 2024-12-30 | Staskey Norm |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2024-08-07 | Joshi Vaidehi |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2024-08-07 | Murphy Keith |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2024-08-07 | Milhous Alison Tjosvold |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2024-08-07 | Gobel David |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2024-08-07 | Cohen Douglas Jay |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2024-08-07 | STERN ADAM K |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of August 7, 2025 or the date of the next annual meeting of stockholders held by the Issuer in 2025, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2024-08-05 | Murphy Keith |
Director |
Award↑
Filing footnotes — Options (right to buy) (Direct)
The option vests in 3 equal annual installments on each of August 5, 2025, August 5, 2026 and August 5, 2027. |
Options (right to buy)
|
574,923 |
| 2024-08-05 | Murphy Keith |
Director |
Award↑
Filing footnotes — Options (right to buy) (Direct)
The option becomes exercisable if, after the grant date, the closing sales price of the Common Stock, as reported on the Nasdaq Capital Market (based on a 90-trading day average), is at least $1.53 (subject to adjustment for stock splits), as confirmed by the Board of Directors or a committee thereof. |
Options (right to buy)
|
143,731 |
| 2023-11-17 | STERN ADAM K |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2023-11-17 | Joshi Vaidehi |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2023-11-17 | Murphy Keith |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2023-11-17 | Gobel David |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2023-11-17 | Milhous Alison Tjosvold |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2023-11-17 | Cohen Douglas Jay |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 17, 2024 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2023-11-15 | Gobel David |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.615 to $1.64, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. |
Common Stock
|
19,607 |
| 2022-11-10 | Joshi Vaidehi |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2022-11-10 | Cohen Douglas Jay |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2022-11-10 | STERN ADAM K |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2022-11-10 | Milhous Alison Tjosvold |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2022-11-10 | Murphy Keith |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2022-11-10 | Gobel David |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The reported securities are represented by restricted stock units, which shall vest on the earlier of November 9, 2023 or the date of the next annual meeting of stockholders held by the Issuer, subject to acceleration in the event of a change of control. |
Common Stock
|
19,607 |
| 2022-08-31 | JURGENSEN THOMAS E |
General Counsel & Secretary |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shares will vest on a quarterly basis over a period of forty-eight (48) months from August 31, 2022. |
Stock Option (Right to Buy)
|
40,000 |
| 2022-08-31 | Miner Jeffrey N. |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shares will vest on a quarterly basis over a period of forty-eight (48) months from August 31, 2022. |
Stock Option (Right to Buy)
|
40,000 |
| 2022-08-31 | Murphy Keith |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shares will vest on a quarterly basis over a period of forty-eight (48) months from August 31, 2022. |
Stock Option (Right to Buy)
|
40,000 |
| 2022-03-08 | Joshi Vaidehi |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2022-03-08 | Joshi Vaidehi |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shares vest and become exercisable over twelve equal quarterly installments measured from March 8, 2022. |
Stock Option (Right to Buy)
|
35,000 |
| 2021-10-07 | Milhous Alison Tjosvold |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. |
Stock Option (Right to Buy)
|
17,500 |
| 2021-10-07 | Miner Jeffrey N. |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $30.00 per share. |
Stock Option (Right to Buy)
|
12,500 |
| 2021-10-07 | Murphy Keith |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. |
Stock Option (Right to Buy)
|
17,500 |
| 2021-10-07 | Miner Jeffrey N. |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $35.00 per share. |
Stock Option (Right to Buy)
|
12,500 |
| 2021-10-07 | Gobel David |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. |
Stock Option (Right to Buy)
|
17,500 |
| 2021-10-07 | JURGENSEN THOMAS E |
General Counsel & Secretary |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/16th of the option shares shall vest and become exercisable on January 7, 2022 and on each three-month anniversary thereafter. |
Stock Option (Right to Buy)
|
52,023 |
| 2021-10-07 | STERN ADAM K |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. |
Stock Option (Right to Buy)
|
17,500 |
| 2021-10-07 | Miner Jeffrey N. |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/16th of the option shares shall vest and become exercisable on January 7, 2022 and on each three-month anniversary thereafter. |
Stock Option (Right to Buy)
|
52,023 |
| 2021-10-07 | Murphy Keith |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $30.00 per share. |
Stock Option (Right to Buy)
|
60,000 |
| 2021-10-07 | Murphy Keith |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option becomes exercisable, if at all, if the 45-day moving average closing price of the Issuer's common stock on The Nasdaq Stock Market LLC exceeds $35.00 per share. |
Stock Option (Right to Buy)
|
60,000 |
| 2021-10-07 | Cohen Douglas Jay |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shares shall vest and become exercisable on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. |
Stock Option (Right to Buy)
|
17,500 |
| 2021-10-06 | Hess Thomas |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2021-08-17 | Cohen Douglas Jay |
Director |
Buy↑
|
Common Stock
(I)
|
1,000 |